Traditional chinese patent medicines for cancer treatment in china: A nationwide medical insurance data analysis

Oncotarget

Volumn 6, Issue 35, 2015, Pages 38283-38295

  Wu, Min ^a   Lu, Peng ^c   Shi, Luwen ^a   Li, Shao ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TSINGHUA UNIVERSITY   (China)

^c INSTITUTE OF AUTOMATION   (China)

Author keywords

Cancer treatment; Herb drug network; Medical insurance; Nationwide survey; Traditional chinese medicine

Indexed keywords

AIDI; CAPECITABINE; CARBOPLATIN; CHONGCAOJUNFAJIAO; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; FUFANGBANMAO; FUFANGKUSHEN; FUFANGZAOFAN; GEMCITABINE; HUACHANSU; HUANGQI; KANGAI; KANGLAITE; OXALIPLATIN; PACLITAXEL; PINGXIAO; PIRARUBICIN; SHENQIFUZHENG; TEGAFUR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIAOAIPING; YADANZIYOU; YIXUESHENG; ZHENQIFUZHENG; ANTINEOPLASTIC AGENT; HERBACEOUS AGENT;

ARTICLE; BLADDER CANCER; CANCER PATIENT; CHINA; CHINESE MEDICINE; CONTROLLED STUDY; DATA ANALYSIS; ESOPHAGUS CANCER; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; NASOPHARYNX CANCER; PANCREAS CANCER; PATENT; WESTERN MEDICINE; CLINICAL PRACTICE; CLUSTER ANALYSIS; DRUG UTILIZATION REVIEW; FACTUAL DATABASE; HEALTH; HEALTH CARE SURVEY; NEOPLASMS; TIME FACTOR; TRENDS; UTILIZATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; CLUSTER ANALYSIS; DATABASES, FACTUAL; DRUG UTILIZATION REVIEW; DRUGS, CHINESE HERBAL; HEALTH CARE SURVEYS; HUMANS; INSURANCE, HEALTH; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; PRACTICE PATTERNS, PHYSICIANS'; TIME FACTORS; URBAN HEALTH;

EID: 84947809792     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5711     Document Type: Article

References (17)

1. Normile D. Asian medicine: The new face of traditional Chinese medicine. Science. 2003; 299:188-190.
2. Ministry of Human Resources and Social Security of the People's Republic of China. China's National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs Catalog (2009 edition). China Labour and Social Security Publishing House. 2009; 12-1.
3. Tong B, Ding N, Wei Q. Analysis of the Utilization of Antineoplastic Agents in Our Hospitals during the Period of 2009-2011. China Pharmacy. 2012; 23:3960-3963.
4. Wang J, Lu M, Zhang G, Lu H. Utilization of Antitumor Drugs in Changshu Hospital Affiliated to Soochow University during 2010-2013. Evaluation and analysis of drug-use in hospitals of China. 2014; 14:908-912.
5. Xu Y, Wang X, Luan W. Analysis on Drug Use in PLA General Hospital During 2008-2010. Evaluation and analysis of drug-use in hospitals of China. 2012; 12:109-113.
6. Wang CY, Bai XY, Wang CH. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med. 2014; 42:543-59.
7. Liang X, Li H, Li S. A novel network pharmacology approach to analyse traditional herbal formulae: the Liu-wei-di-huang Pill as a case study. Molecular BioSystems. 2014; 10:1014-1022.
8. Adepoju L, Wanjiku S, Brown M, Qu W, Williams M, Redfern RE, Sferra JJ. Effect of insurance payer status on the surgical treatment of early stage breast cancer: data analysis from a single health system. JAMA Surg. 2013; 148:570-2.
9. Robbins AS, Pavluck AL, Fedewa SA, Chen AY, Ward EM. Insurance status, comorbidity level, and survival among colorectal cancer patients age 18 to 64 years in the National Cancer Data Base from 2003 to 2005. J Clin Oncol. 2009; 27:3627-33.
10. Chen W, Zhang S, Zheng R, Zeng H, Zou X, Zhao P, Wu L, Li G, Hao J. Report of Cancer Incidence and Mortality in China, 2009. China Cancer. 2013; 22:2-12.
11. Kang H, Ahn KS, Cho C, Bae HS. Immunomodulatory effect of Astragali Radix extract on murine TH1/TH2 cell lineage development. Biol Pharm Bull. 2004; 27:1946-50.
12. Lee YS, Han OK, Park CW, Suh SI, Shin SW, Yang CH, Jeon TW, Lee ES, Kim KJ, Kim SH, Yoo WK, Kim HJ. Immunomodulatory effects of aqueous-extracted Astragali radix in methotrexate-treated mouse spleen cells. J Ethnopharmacol. 2003; 84:193-8.
13. Zeng XL, Li XA, Zhang BY. Immunological and hematopoietic effect of Codonopsis pilosula on cancer patients during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992; 12:607-8. 581.
14. Zhuang SR, Chen SL, Tsai JH, Huang CC, Wu TC, Liu WS, Tseng HC, Lee HS, Huang MC, Shane GT, Yang CH, Shen YC, Yan YY, Wang CK. Effect of citronellol and the Chinese medical herb complex on cellular immunity of cancer patients receiving chemotherapy/radiotherapy. Phytother Res. 2009; 23:785-790.
15. Wang Z, Zhang J, Wang Y, Xing R, Yi C, Zhu H, Chen X, Guo J, Guo W, Li W, Wu L, Lu Y, Liu S. Matrine, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases. Carcinogenesis. 2013; 34:128-138.
16. Xie SB, He XX, Yao SK. Matrine-induced autophagy regulated by p53 through AMP-activated protein kinase in human hepatoma cells. Int J Oncol. 2015; 47:517-26.
17. Li S, Zhang B, Jiang D, Wei YY, Zhang NB. Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae. BMC Bioinformatics. 2010; 11:S6.